KLIKCAR 50mg

KLIKCAR 50mg is based on research involving GW501516, a synthetic small molecule developed to investigate activation of the Peroxisome Proliferator-Activated Receptor Delta (PPAR-δ). Unlike peptide therapeutics that act through membrane-bound receptors, GW501516 functions by activating a nuclear transcription factor, influencing the expression of hundreds of genes involved in energy metabolism. Scientific interest in GW501516 emerged during research into obesity, dyslipidaemia, metabolic syndrome and cardiovascular disease. Early laboratory and clinical investigations suggested that activation of PPAR-δ could influence lipid metabolism, fatty acid oxidation, skeletal muscle physiology and insulin sensitivity. Because skeletal muscle contains high concentrations of PPAR-δ receptors, researchers also investigated its role in endurance adaptation and exercise metabolism. Animal studies demonstrated remarkable metabolic changes, including increased reliance on fatty acids as an energy source and improved endurance performance. However, despite promising early findings, development of GW501516 for clinical use was discontinued following long-term toxicology studies in rodents. These studies identified increased tumour formation in multiple organ systems after prolonged exposure at experimental doses. Although the direct relevance of these findings to humans remains uncertain, they represent an important part of the scientific literature and continue to influence research involving PPAR-δ agonists. Today, GW501516 remains a research compound that has contributed substantially to scientific understanding of metabolic regulation, mitochondrial biology and nuclear receptor signalling.

The Peroxisome Proliferator-Activated Receptors (PPARs) are a family of nuclear receptors that regulate gene expression in response to nutritional and metabolic signals. Three major subtypes have been identified: • PPAR-α — primarily involved in liver lipid metabolism. • PPAR-γ — involved in adipocyte differentiation and insulin sensitivity. • PPAR-δ (also called PPAR-β/δ) — widely distributed throughout skeletal muscle, heart, adipose tissue and other metabolically active organs. Among these receptors, PPAR-δ is particularly important in regulating energy utilisation during prolonged physical activity. Activation of PPAR-δ promotes transcription of genes involved in: • Fatty acid transport • Fatty acid oxidation • Mitochondrial function • Oxidative metabolism • Glucose utilisation • Skeletal muscle adaptation These biological effects have made PPAR-δ an important research target in metabolic medicine.

MOLECULAR MECHANISM Unlike conventional receptor agonists that rapidly alter cellular signalling, GW501516 enters cells and binds directly to intracellular PPAR-δ receptors. Following activation: 1. PPAR-δ forms a heterodimer with the Retinoid X Receptor (RXR). 2. The receptor complex binds to specific DNA sequences known as PPAR Response Elements (PPREs). 3. Gene transcription is modified. 4. Cellular metabolism gradually adapts through altered protein synthesis. Because these changes require gene expression, many physiological effects develop over days to weeks rather than immediately. EFFECTS ON LIPID METABOLISM One of the best-characterised actions of PPAR-δ activation involves regulation of fatty acid metabolism. Experimental studies suggest increased expression of proteins involved in fatty acid transport, mitochondrial uptake of fatty acids, β-oxidation and lipid utilisation during exercise. Researchers have observed increased reliance on stored fat as an energy source in several experimental models. MITOCHONDRIAL BIOLOGY PPAR-δ activation has been associated with increased expression of genes involved in mitochondrial biogenesis, oxidative enzyme activity, respiratory capacity and cellular energy production. Animal studies frequently demonstrate increased oxidative muscle fibres following prolonged PPAR-δ activation.

SKELETAL MUSCLE RESEARCH Skeletal muscle contains particularly high concentrations of PPAR-δ receptors. Laboratory investigations suggest activation influences oxidative muscle fibre development, fat utilisation, exercise metabolism, endurance physiology and metabolic flexibility. One of the most widely cited mouse studies demonstrated substantial increases in running endurance following genetic activation of PPAR-δ pathways. EXERCISE PHYSIOLOGY Researchers became interested in GW501516 because of its apparent influence on endurance metabolism rather than maximal strength. Experimental studies have investigated time to exhaustion, oxygen utilisation, fat oxidation, glycogen preservation and exercise efficiency. Animal studies consistently demonstrate increased reliance on lipid metabolism during prolonged exercise. Human investigations remain considerably more limited, and these studies do not establish improvements in athletic performance under all conditions. INSULIN SENSITIVITY Several early investigations examined whether PPAR-δ activation influences glucose regulation. Reported findings include improvements in insulin sensitivity, fasting triglycerides, HDL cholesterol and lipid oxidation. Researchers proposed that increased fatty acid utilisation may reduce lipid accumulation within skeletal muscle and liver, thereby improving insulin signalling. HUMAN CLINICAL RESEARCH Compared with animal research, human clinical investigations have been relatively limited. Early studies evaluated lipid profiles, HDL cholesterol, triglycerides, insulin sensitivity and metabolic biomarkers. Some studies reported favourable changes in selected metabolic parameters. However, clinical development was discontinued before larger outcome trials could establish long-term efficacy or safety. CARDIOVASCULAR RESEARCH PPAR-δ is expressed within vascular tissue. Research areas include endothelial function, lipoprotein metabolism, vascular inflammation, atherosclerosis and cardiac energy metabolism. Although laboratory findings have been encouraging, definitive clinical conclusions remain unavailable.

GW501516 is an orally active small molecule. Experimental pharmacokinetic studies have investigated: • Oral absorption • Tissue distribution • Hepatic metabolism • Elimination Unlike peptide therapeutics, the compound is not degraded through proteolysis but instead undergoes hepatic metabolism. Additional pharmacokinetic research remains ongoing.

SAFETY CONSIDERATIONS The safety profile of GW501516 represents one of the most important aspects of its research history. During long-term toxicology studies conducted in rodents, investigators observed increased tumour formation involving multiple organs after prolonged administration. These findings ultimately resulted in discontinuation of clinical development. Several important considerations should be recognised: • The animal studies used prolonged exposure under experimental conditions. • The relationship between these findings and potential human risk has not been fully established. • Because clinical development ceased, long-term human safety data remain unavailable. RESEARCH LIMITATIONS Current understanding of GW501516 is limited by: • Relatively small human studies. • Lack of long-term clinical outcome trials. • Discontinuation of pharmaceutical development. • Significant differences between animal and human physiology. • Uncertainty regarding long-term safety. For these reasons, interpretation of the available literature requires careful consideration of both the promising metabolic findings and the unresolved safety concerns.

Although GW501516 itself is no longer undergoing pharmaceutical development, research into PPAR-δ biology continues. Current investigations include: • Selective PPAR modulators • Nuclear receptor signalling • Exercise metabolism • Mitochondrial adaptation • Metabolic disease • Precision medicine • Gene regulation Understanding how PPAR-δ regulates cellular metabolism continues to influence development of newer metabolic therapies.